AXIMOTCPharmaceutical PreparationsFiscal year ends December 31

AXIM BIOTECHNOLOGIES, INC.

Financials through Q2 FY2024, quarter ended Jun 30, 2024Last filing: 10-Q on Aug 19, 2024

$0.00+0.00 (+2.00%)

Close on Oct 19, 2026

Community

Notes and questions about Axim Biotechnologies from other investors

Discussion opens with sign-in. Posts will be able to point at any number on these pages, so everyone sees exactly which figure is being discussed.

Parsed from the XBRL in Axim Biotechnologies's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is AXIM.

Revenue growth254.6% · median 0.6%

Operating margin-2490.3% · median -302.0%

Net margin-4452.1% · median -296.3%

Advertisement
300 × 250